Underberg Sharon E. sold $6.1M of IDXX

Underberg Sharon E. (EVP, GC & Corporate Secretary) sold 8,906 shares of IDEXX LABORATORIES INC /DE (IDXX) at an average of $688.59 ($688.25–$690.02, $6.13M total) across 3 trades on 2026-11-04.

Original reporting
SEC EDGAR · Underberg Sharon E.
Published Nov 5, 2026, 10:02 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 10:06 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$IDXX
Bearish
medium confidence
Mentioned
$IDXX
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$IDXXBearishLow
01

Why it matters

The disclosed sale may prompt short sellers and reduce bullish sentiment, but the effect is likely modest.

02

Market read

A senior officer's $6M share sale is a primary disclosure that could slightly weigh on IDXX's stock.

03

What to watch

Potential tax planning or pre-arranged liquidity needs not reflected in the filing.

Relevance 6/10Novelty 5/10Timing: post-market on 2026-11-04

Background

Form 4 filings disclose insider transactions; investors monitor them for signals about company outlook.

Company-level read

Ticker impact

$IDXXBearishMedium confidence
Context

EVP and General Counsel Sharon E. Underberg sold 8,906 shares for $6.13M, reducing her stake to 7,169 shares.

Expected impact

downward pressure as market prices in the insider sell

Evidence & confidence

The sale is sizable for an insider and disclosed via a Form 4, a primary source, but the amount is modest relative to market cap.

Market effects

Minimal impact on the broader diagnostics sector; only a single insider transaction.

No regional effect beyond the company's share price.

Limited to investors tracking insider activity.

Counterpoint

The sale could be a routine portfolio rebalancing rather than a negative signal.

Key entities

  • Sharon E. Underberg

    Executive Vice President, General Counsel & Corporate Secretary of IDEXX Laboratories.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$IDXXHighAI 8/10

IDEXX Laboratories Inc (IDXX) (Q3 2026) Earnings Call Highlights: Raised Outlook

IDEXX Laboratories reported Q3 2026 earnings, raising its full-year organic growth outlook to nearly 10% despite challenges. US clinic visits declined 1.8%, and macro pressures impacted puppy/kitten adoptions. CoVet acquisition is expected to dilute EPS by $0.13 in 2026. Global Rapid Assay revenues grew 1% organically. The company attributed growth to innovations, record instrument placements, and higher-quality visits.